A pill designed to clear a protein linked to Alzheimer’s has to get through the gut and into the brain. Oyster Therapeutics, a London drug development startup, has raised $60 million to advance an experimental treatment for tau, a protein that can accumulate in an unhealthy form in the brain.
Oyster’s chief executive says the drug is designed to split into smaller pieces that can cross biological barriers. Inside a cell, the pieces reassemble and direct the cell’s own disposal machinery to break down the target protein. The work is still at the preclinical stage. The company aims to bring the drug into human studies and has yet to give a timeline.
